PharmaCyte Biotech, Inc.

- 04 NOV 2013
Nuvilex Announces Cloning of Cells for Future Phase 3 Clinical Trials Initiated by Inno Biologics
SILVER SPRING, MD–(Marketwired – Nov 4, 2013) – PharmaCyte Biotech, Inc. (OTCQB: NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that cloning of the cancer-drug-activating cells required for PharmaCyte Biotech’s future Phase 3 clinical trials has begun at Inno Biologics in its cGMP-compliant facilities. Following
Read more →
- Posted in
- News
- 17 SEP 2013
Nuvilex Contracts With Inno Biologics, an FDA-Compliant Provider, for Initial Generation of Cloned Cells for Future Phase 3 Clinical Trials
SILVER SPRING, Md., Sept. 17, 2013 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX) (“Company”), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today it has contracted Inno Biologics Sdn. Bhd. to generate cell clones that are the basis of the Company’s future Phase 3 cancer clinical trials.
Read more →
- Posted in
- News
- 11 SEP 2013
Nuvilex Eyes FDA Fast Track After ABRAXANE Approved for Pancreatic Cancer
NEW YORK, NY–(Marketwired – Sep 11, 2013) – PharmaCyte Biotech, Inc. (OTCQB: NVLX) and its shareholders enjoyed what could be a dress rehearsal of their own future with the Food and Drug Administration’s (FDA) Fast Track program. Late last week Celgene announced that the FDA has approved its supplemental new drug application for ABRAXANE® when
Read more →
- Posted in
- News
- 10 SEP 2013
Nuvilex Contracts Fisher BioServices, Inc. for Long-Term Storage of Cells for Future Phase 3 Clinical Trials
SILVER SPRING, MD–(Marketwired – Sep 10, 2013) – PharmaCyte Biotech, Inc. (OTCQB: NVLX) (Company), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today it has contracted Fisher BioServices, Inc. for the long-term storage of cells that will be required for its future Phase 3 and other cancer
Read more →
- Posted in
- News
- 23 AUG 2013
Nuvilex, Inc. Restructures Corporate Operations to Reflect Biotechnology Focus
PharmaCyte Biotech Launches New Corporate Website SILVER SPRING, MD–(Marketwired – Aug 23, 2013) – PharmaCyte Biotech, Inc. (OTCQB:NVLX) (Company), an international biotechnology company and former provider of natural products, as well as cell and gene therapy solutions for the treatment of diseases, announced today that the Company has restructured corporate operations in an effort to
Read more →
- Posted in
- News

Press Releases

Nuvilex Announces Cloning of Cells for Future Phase 3 Clinical Trials Initiated by Inno Biologics

Nuvilex Contracts With Inno Biologics, an FDA-Compliant Provider, for Initial Generation of Cloned Cells for Future Phase 3 Clinical Trials

Nuvilex Eyes FDA Fast Track After ABRAXANE Approved for Pancreatic Cancer

Nuvilex Contracts Fisher BioServices, Inc. for Long-Term Storage of Cells for Future Phase 3 Clinical Trials

Nuvilex, Inc. Restructures Corporate Operations to Reflect Biotechnology Focus